+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Transcatheter Embolization & Occlusion Devices Market Forecast 2020-2030

27 September 2020

Transcatheter Embolization & Occlusion Devices Market Forecast 2020-2030: Forecasts and Analysis By Type, By Application, and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Transcatheter Embolization & Occlusion Devices sector analysis.

According to the report published by Visiongain, the Transcatheter Embolization & Occlusion Devices market was valued at approximately USD xx billion in 2019. The use of minimally invasive endovascular methods in medicine was expanding tremendously. The surgical treatment of almost any organ disorder has been revolutionized thanks to techniques based on real-time photo instructions for the movement of elastic catheters from a shallow, easily accessible blood vessel to a remote, deep blood vessel. The performance of vascular embolization, a techniques in which an occlusive agent is provided by a catheter for blocking flow in a target blood vessel, is a common paradigm in endovascular procedures. Embolization was carried out for several medical conditions, including the blood supply for hemorrhagic stomach ulcer and the eradication of a cancer in the liver. A variety of occlusive arms, including metal bobbins, injectable glues and embolic particles, are presently commercially usable. That class of embolic agent has its respective strengths and weaknesses and is well-suited for different medical specialty scenarios. Embolic particles have been produced and remain the most flexible embolic agent; in fact, they are the ideal platform to provide a highly localized therapeutic transcatheter. In the review, we sum up the present methods in particle synthesis and present the merits of the latest technology, such as microfluidics, with enormous potential to promote personalized particle design.

Transcatheter Embolization & Occlusion Devices Market is witnessing Growth due to factors such as
In order for the manufacture of PVA particles for embolotherapy, the surface of a compressed block of PVA is rasped or rasped; the results are sort through sieves to separate the particles according to their size. The variability of particle size and shape is an annoyance of this process. Too large a particle is too close in a vessel and probably causes ineffective embolization. Alternatively, too small a particle will travel too far and increase the risk of damage to the organ. Last cases include facial nerve palsy after existing carotid artery embolism and tissue necrosis after pelvic embolization, from original formulations of PVA. In fact, PVA molecules have a strong friction coefficient and can add up. This has two unwanted consequences. First, the particle's effective size increases considerably, leading to proximal.

With continue advancement in transcatheter technology and operator expertise, all unwanted vascular communication should be amenable to transcatheter embolization
Transcatheter embolization of congenital or acquired superfluous vascular structure has become routine procedures performed by interventional pediatric cardiologists. Embolization procedure is often part of a collaborative effort with cardiac surgeons to palliate complex congenital heart defect, such as in embolizing aortopulmonary collateral arteries in patient with single ventricle physiology. In other cases, the procedure is the definitive treatment as in embolizing coronary artery fistula. Pediatric cardiologists performing embolization procedures should be familiar with available technologies as well as understand the underlying cardiac anatomy and pathophysiology. Some of the technologies are used only by interventional radiologists but may be useful to pediatric cardiologists.

Shift in Trends

Particles for endovascular embolization have evolved
Particles for endovascular embolization have evolved from materials such as lead pellets, muscle, fat, autologous blood clot and gelatin sponge to particles comprised of complex polymers with varying biochemical properties which can be modified to carry therapeutic payloads. Currently available particles span a broad spectrum of sizes, shapes, and materials and compose a versatile toolkit applicable to a myriad of disease processes. This toolkit, and by extension the clinical utility and applicability, is poised to expand substantially through emerging technologies that may revolutionize the accuracy and efficacy of particles.

Embolotherapy is a major aspect of Interventional Radiology
Embolotherapy is a major aspect of Interventional Radiology and, as such, there are an increasing number of indications, ongoing research, and new developments. Numerous materials have been used for embolization and, recently, many new embolic agents, and devices have been developed. In this chapter we review the most common materials used in daily practice of most interventional radiologists. In this two-volume textbook, each chapter discusses separately the optimal embolic materials related to the corresponding clinical indications.

Transcatheter embolization is a safe and effective method to achieve vascular occlusion.
Embolization procedures have been applied in almost every organ system to occlude congenital or acquired vascular anomalies, to control hemorrhage, to palliate neoplasm, and as a preoperative adjunct to minimize intraoperative blood loss. For the purposes of this review, the term embolization refers to the intentional placement of foreign material in vascular lumina in order to provide therapeutic mechanical and/or gradual thrombogenic, proliferative, or inflammatory closure of the blood vessels. Interventional pediatric cardiologists perform a variety of embolization procedures using several devices and materials. This review will describe the embolization technologies commonly used by or useful to pediatric cardiologists. In addition, the concomitant use of several technologies and operator-modified technologies will be illustrated. This review will also discuss a variety of clinical applications of embolization procedures in pediatric cardiology.

What is the future of the Transcatheter Embolization & Occlusion Devices market? Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.

The market is divided into peripheral vascular diseases, oncology, neurology and other diseases based on application. The growth of the sector is predicted to be spurred on by increased cases of fatal neurological conditions, such as brain aneurysm and cerebral malformations throughout the globe. More than 140 Gugelielmi detachable coils in several sizes, used in more than 125,000 patients around the world, are currently available on the market, according to the Society of Neurointerventional Surgery. Therefore, during the forecast period, the market for brain aneurysm will grow significantly.
Due to the efficient treatment of liver and kidney cancer the oncology segment is expected to be the most effective CAGR. Embolization is one of the most common treatment methods for various cancers including liver, kidney, breast, pancreas etc. Of these, hepatocellular or liver cancer is the most common form among illness that is treated by embolization. Hepatocellular carcinoma is the fifth leading cause of cancer deaths worldwide, according to the National Center for Biotechnology

Regional Market Analysis
The majority of income in 2019 was shared between North America and Europe. Some of the factors driving demand for TEO tools in these regions are the availability of advanced medical technology, an established regulatory framework, and skilled health professionals to perform the treatment. During the forecast period, both regions would tend to be dominant. This growth is because of the large objective population base, increased expenditure and widespread use of advanced healthcare technology. In the forecast period, Asia-Pacific is expected to record the fastest CAGR by 12.0%. Rapidly growing medical tourism industry in emerging economies, such as India, China, and Malaysia, is attracting cancer patients across the globe. As a result, demand for TEO treatments in these countries is expected to rise swiftly, thereby driving the regional market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biologics Market Report 2024-2034

The biologics market is estimated at US$447 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034.

20 November 2023


Visiongain Publishes mRNA Vaccines Market Report 2023-2033

The global mRNA Vaccines market is estimated at US$11,773.3 million in 2023 and is projected to grow at a CAGR of 10.5% during the forecast period 2023-2033.

08 November 2023


Visiongain Publishes Stem Cell Technologies and Applications Market Report 2023-2033

The global Stem Cell Technologies and Applications market is estimated at US$10,059.6 million in 2023 and is projected to grow at a CAGR of 8.7% during the forecast period 2023-2033.

06 November 2023


Visiongain Publishes Neurology Clinical Trials Market Report 2023-2033

The global Neurology Clinical Trials market is valued at US$9,609.2 million in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period 2023-2033.

01 November 2023